HomeAprepitantAprepitant + Midazolam

Does Aprepitant Interact with Midazolam?

Aprepitant and Midazolam have a major drug interaction according to U.S. FDA drug labeling data. Increased midazolam exposure may increase risk of adverse reactions with 3-day aprepitant regimen; dose reduction may be warranted. The mechanism involves cyp3a4 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Aprepitant Class
Substance P/Neurokinin-1 Receptor Antagonist
Midazolam Class
Benzodiazepine
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Aprepitant and Midazolam occurs because cyp3a4 inhibition. Clinically, this means increased midazolam exposure may increase risk of adverse reactions with 3-day aprepitant regimen; dose reduction may be warranted. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Aprepitant and your doctor is considering prescribing Midazolam (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Aprepitant(Aponvie)+💊 Midazolam

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Substance P/Neurokinin-1 Receptor Antagonist
Drug B class
Benzodiazepine
Source
NLP:aprepitant

What this means in plain English

Increased midazolam exposure may increase risk of adverse reactions with 3-day aprepitant regimen; dose reduction may be warranted.

What the FDA label says

"CYP3A4 inhibition"

📖 Source: NLP:aprepitant

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Aprepitant and Midazolam against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.